Fostamatinib – Warm Autoimmune Hemolytic Anemia
A Phase 3, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of fostamatinib in warm Autoimmune Hemolytic Anemia (wAIHA) subjects.
Phase 3 – wAIHA
Fostamatinib – COVID-19
A Phase 3, multi-center, randomized, double-blind, placebo-controlled, adaptive design study to evaluate the safety and efficacy of fostamatinib in COVID-19 subjects.
Phase 3 - COVID-19